To: gizwick who wrote (53995 ) 2/6/2025 2:19:32 PM From: E_K_S Respond to Re: Phibro Anl Htlh A (PAHC) +9.03% LAST $24.39/share Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. The company provides a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. In addition to animal health and mineral nutrition products, Phibro manufactures and markets specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries. Currently, Phibro focuses on regions where the majority of livestock production is consolidated in large commercial farms such as the U.S., Brazil, China, Russia, Mexico, Australia, Turkey, Israel, Canada and Europe. Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance Highlights for the three months ended December 31, 2024 (compared to the three months ended December 31, 2023)Net sales of $309.3 million, an increase of $59.3 million, or 24% Net income of $3.2 million, an increase of $1.9 million Diluted earnings per share of $0.08, an increase of $0.05 Adjusted EBITDA of $48.2 million, an increase of $18.7 million, or 64% Adjusted net income of $21.9 million, an increase of $8.5 million, or 63% Adjusted diluted EPS of $0.54, an increase of $0.21, or 64% Net sales of $1.25 billion to $1.30 billion Adjusted EBITDA of $172 million to $180 million PAHC continues to be a reversion to the mean play but need to look at last 10 years. Maybe another 40% upside to $34 but a lot depends on if they can maintain margins and grow revenues w/ new products/acquisitions.Acquisition impact: The $350 million acquisition of Zoetis' medicated feed additive (MFA) portfolio in 2024 is expected to add approximately $200 million in revenue for the eight-month period in fiscal year 2025 2 7 . This substantial addition could drive the company's performance closer to historical levels. Improved financial metrics: PAHC's adjusted net income increased by 63% to $21.9 million, and adjusted diluted EPS rose 64% to $0.54 in the recent quarter 9 . These improvements indicate a potential return to stronger financial performance. Recent and Upcoming Products/Services In the last 24 months:Rejensa® joint supplement for dogs has gained customer acceptance 3 . New poultry product introductions in Latin America have driven vaccine sales growth of 22% 2 . Expanded performance products for personal care ingredients, leading to 27% segment growth 2 . Early-stage atopic dermatitis compound for companion animals 3 . Mid-stage pain product for animals 3 . Early-stage oral care compound for pets 3 . Collaboration with Rejuvenate Bio, Inc. on gene therapy for mitral valve disease in dogs 3 . Continued development of plant protection products, including microbials for seed treatment and plant application 3 . Integration and expansion of the acquired Zoetis MFA portfolio, which is expected to contribute significantly to revenue growth 2 7 . Made 2 Buys in 11/2023 and an average cost of $10/share. Another Reversion to the mean play. Stock has blasted through it's SMA(200) weekly at $18.00/share. Maybe another +65% if you go back 10 years w/ a $60/share price target. PAHC completed the acquisition of Zoetis' medicated feed additive (MFA) product portfolio and certain water-soluble products on October 31, 2024 at a cost of $350 million. That was a huge investment as the current market cap is only $906 million. Stock +140% in 14 months but is set up to go much higher. Peeled off 20% over the last 2 weeks. Plan is to scale out w/ more sales every 20% higher. Not sure PAHC will get back to it's 10 year high but has a good chance of reaching it's 5 year high at/near $30/share. Stock was first mentioned by gizwick in his post #53995 6/2014 at/near $30/share
